Department of Family Medicine, Clalit Health Services, 56 Chen St., Central District, Rehovot, Israel.
Family Medicine Department, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Isr J Health Policy Res. 2022 Mar 25;11(1):17. doi: 10.1186/s13584-022-00528-7.
Readmission after hospitalization for acute COPD exacerbation (AE-COPD) has been proposed as a healthcare quality indicator (QI) in Israel. We studied patients hospitalized for AE-COPD, towards determining whether AE-COPD readmission is an appropriate national QI in order to improve COPD patient care.
Data were retrieved for all Clalit Health Service (CHS) members age 40-90 years hospitalized in CHS hospitals during 2016 with a diagnosis of acute COPD exacerbation. Information retrieved included demographics, medical history, Charleson comorbidity score, readmissions within 90 days, chronic medication use and family physician and pulmonologist visits. Patients readmitted within 90 days were compared to those who were not readmitted. Patients were also analyzed according to whether they were hospitalized during the year before the index hospitalization.
In 2016 there were 70,601 members with a recorded diagnosis of COPD in CHS. Of these, 1,203 patients (1.7%) were hospitalized in a CHS hospital with a diagnosis of acute COPD exacerbation during 2016. Average age was 70.6 years, 63% were men. 78% were active smokers. 61% of the patients were readmitted to internal medicine wards within 90 days of the index hospitalization. Patients who were readmitted were more likely to have been hospitalized during the year before the index hospitalization (Odds ratio (OR) 2.5, Confidence Interval ((CI)(1.85, 3.38)) and had a higher Charlson comorbidity score (OR 1.07 (CI 1.01, 1.11)). Healthcare utilization by patients who were readmitted, both before and after admission, was generally greater. One yr mortality was 15.1% and 9.2% in those readmitted and not readmitted, respectively (p = 0.003).
Readmitted COPD patients appear to be the sickest group of COPD patients with advanced disease and poor prognosis, and it may not be possible to prevent readmissions. This questions the utility of COPD readmissions as a healthcare quality indicator.
在以色列,住院治疗急性 COPD 加重(AE-COPD)后的再入院被提为医疗质量指标(QI)。我们研究了因 AE-COPD 住院的患者,以确定 AE-COPD 再入院是否是改善 COPD 患者护理的合适的国家 QI。
检索了 2016 年在 Clalit 医疗服务(CHS)医院住院治疗的所有年龄在 40-90 岁、诊断为急性 COPD 加重的 CHS 成员的数据。检索到的信息包括人口统计学、病史、Charlson 合并症评分、90 天内再入院、慢性药物使用以及家庭医生和肺病专家就诊情况。比较了 90 天内再入院的患者和未再入院的患者。还根据患者是否在指数住院前一年住院进行了分析。
2016 年,CHS 有 70601 名记录在案的 COPD 患者。其中,1203 名(1.7%)患者因急性 COPD 加重在 CHS 医院住院治疗。平均年龄为 70.6 岁,63%为男性。78%为主动吸烟者。61%的患者在指数住院后 90 天内被重新收治到内科病房。再入院的患者更有可能在指数住院前一年住院(优势比(OR)2.5,置信区间(CI)(1.85,3.38)),且 Charlson 合并症评分更高(OR 1.07(CI 1.01,1.11))。再入院患者的医疗保健利用情况,包括入院前后,普遍较高。1 年死亡率分别为 15.1%和 9.2%(p=0.003)。
再入院的 COPD 患者似乎是患有晚期疾病和预后不良的 COPD 患者中最病重的一组,可能无法预防再入院。这对 COPD 再入院作为医疗质量指标的效用提出了质疑。